If you have previously registered for this event, please login below:

Registration is required to attend this event. Please register now.
First Name*
Last Name*
Street Address Line 2
Zip Code*
Work Phone
Company URL
CCFA may contact me by email. 
Please select which best describes you
When were you diagnosed with Crohn's or colitis?
Is this your first time attending a CCFA program?Yes
You must have Javascript and Cookies enabled to access this webcast. Click here for Help.
Please enable Cookies in your browser before registering for the webcast.
*Denotes required.
Why IBD Patients Should Know About Biosimilars

Date: Wednesday, June 01, 2016
Time: 08:00 PM EDT | 7:00 PM CST | 6:00 PM MST | 5:00 PM PST
Duration: 60 mins

While not yet available in the U.S., the Food and Drug Administration recently announced its approval of a biosimilar for the treatment of Crohn’s disease and ulcerative colitis. Join us to learn more about biosimilars and hear from our experts as they answer your questions!

David Rubin, MD
University of Chicago Medicine
Chicago, Illinois

Noa Cleveland, MD
University of Illinois College of Medicine
Chicago, Illinois

This program is supported by a sponsorship from AbbVie, Inc. and an educational grant from Amgen.
Additional support of this program through CCFA’s annual giving programs and donors.